Legislation to remove CMS restrictions on anemia drugs

10/2/2007 | Hill, The

A Democrat and a Republican have introduced legislation in Congress that would overturn a July CMS decision to restrict reimbursements for erythropoiesis-stimulating drugs that treat anemia in cancer patients. The legislation says the CMS policy puts patients at risk by restricting access to the drugs, including Amgen's Epogen and Aranesp and Johnson & Johnson's Procrit.

View Full Article in:

Hill, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY